Cancer Research Annual Meeting 2010 2010 Workshops
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hendrix, M. J. C.
Right arrow Articles by Schatteman, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hendrix, M. J. C.
Right arrow Articles by Schatteman, G. C.
[Cancer Research 62, 665-668, February 1, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Transendothelial Function of Human Metastatic Melanoma Cells

Role of the Microenvironment in Cell-Fate Determination1

Mary J. C. Hendrix2, Richard E. B. Seftor, Elisabeth A. Seftor, Lynn M. Gruman, Lisa M. L. Lee, Brian J. Nickoloff, Lucio Miele, Don D. Sheriff and Gina C. Schatteman

Department of Anatomy and Cell Biology [M. J. C. H., R. E. B. S., E. A. S., L. M. G., L. M. L. L.], Department of Exercise Science [D. D. S., G. C. S.], and The Holden Comprehensive Cancer Center [R. E. B. S., E. A. S., M. J. C. H.], University of Iowa, Iowa City, Iowa 52242, and Department of Pathology, Loyola University Medical Center, Chicago, Illinois 60153 [B. J. N., L. M.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
On the basis of the ability of aggressive melanoma cells to participate in vasculogenic mimicry, particularly their expression of endothelial-associated genes, we examined the plasticity of human metastatic cutaneous melanoma cells with respect to vascular function. Fluorescently labeled metastatic melanoma cells were challenged to an ischemic microenvironment surgically induced in the hind limbs of nude mice. The data reveal the capability of these melanoma cells to express cell-fate determination molecules, normally expressed during embryonic vasculogenesis, and to participate in the neovascularization of circulation-deficient muscle. These results demonstrate the powerful influence of the microenvironment on the transendothelial differentiation of aggressive melanoma cells, and may provide new perspectives on tumor cell plasticity that could be exploited for novel therapeutic strategies.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
A common necessity for development, wound healing, and tumor progression is a blood supply formed by vasculogenic and/or angiogenic events, involving the cooperative interactions of cells with their microenvironment (reviewed in Refs. 1, 2, 3, 4 ). Without question, the constituents of the microenvironment play a key role in the regulation of these events through complex signaling cascades and cell-matrix dynamic reciprocity (2) . The vascularization of tumors, in particular, has been the focus of myriad studies with the ultimate goal of targeting key factors and cells responsible for the formation of vasculature (5, 6, 7) . However, recent evidence has confounded our understanding of tumor vasculature and underscored the complexity of the events involved, including reports of mosaic vessels (tumor- and endothelial-lined vasculature; Ref. 8 ), tumor-lined vasculature (9 , 10) , angiogenic versus nonangiogenic pathways of tumor dissemination (11) , and tumor cell vasculogenic mimicry (12) .

Our knowledge of the molecular determinants of cancer has benefited significantly from microarray analysis technology in recent years. The first molecular classification of human malignant cutaneous melanoma revealed the aberrant expression of multiple molecular phenotypes by the aggressive, but not the nonaggressive, melanoma cells reminiscent of an embryonic-like cell (13) . However, follow-up investigations addressing the putative biological significance of some of these aberrant genes have been slow to emerge.

The present study follows a unique strategic approach using an ischemic microenvironment and challenges malignant melanoma cells to make cell-fate decisions regarding their participation in neovascularization and/or tumor formation. The results demonstrate the influence of the microenvironment on the transendothelial differentiation of aggressive melanoma cells and may provide new perspectives on tumor-cell plasticity that could be exploited for novel therapeutic strategies.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Cell Culture.
The human cutaneous nonaggressive and nonmalignant C81–61 and aggressive, malignant C8161 cell lines have been characterized previously according to their phenotype, invasive and metastatic potential, and clinical significance (14) . These cell lines were maintained in either RPMI 1640 for the C8161 or Ham’s F-10 for the C81–61 (InVitrogen Life Technologies, Inc., Carlsbad, CA) supplemented with 10% fetal bovine serum (Gemini Bioproducts, Calabasas, CA) and 0.1% gentamicin sulfate. Cell cultures were determined to be free of Mycoplasma contamination using the GenProbe rapid detection system (Fisher, Itasca, IL). The C8161 cells that were stably transfected with EGFP3 (pEGFP-N1; Clontech, Palo Alto, CA) were maintained as above with the addition of 400 µg/ml G-418 (Mediatech, Herndon, VA). Transient tumor cell expression of either the green (Ad5 RSV-GFP) or RFP (Ad5 RSV-RFP) was achieved by adenoviral infection (University of Iowa Gene Transfer Vector Core, Iowa City, IA).

Ischemic Mouse Model.
All of the procedures were performed on nude (HFh11nu) mice (Jackson Laboratories, Bar Harbor, ME) according to The University of Iowa Animal Care and Use Committee guidelines. Surgical procedures were followed as has been described previously (15) .

Under anesthesia (91 µg of ketamine + 10 µg of xylazine/gram) the mouse was placed ventral side up, and a 1–1.5-cm incision made in the skin in the left inguinal area. The femoral artery was then ligated twice with 6–0 silk and transected in two places distal to the ligature. Any other large blood vessels distal to the ligature that were visible were also transected. The wound was closed with 4–0 silk, and the hind limbs were gently immobilized and scanned using a laser Doppler imager (Moor Instruments, Inc., Portland, OR), which measures the flux (blood x area-1 x time-1) of blood in the limb as described previously (15) . The mean flux in the operated limb immediately after surgery ranged from 6–13% compared with the unoperated control limb for the mice studied. Four to 8 h after surgery, 1 x 103 or 2 x 103 Ad-RFP-transfected C8161 and C81–61 human melanoma cells were injected i.m. into the ischemic limb.

Five and 20 days later, four mice that had received 1 x 103 and 4 mice that had received 2 x 103 Ad-RFP cells were anesthetized according to modifications of previously described methodologies (8 , 15) . A PE10 catheter was inserted into the abdominal aorta. After anchoring the catheter, the vessel was anterogradely perfused with 250 µg of F-BSLB4 (Vector Laboratories, Burlingame, CA) or a mixture of 250 µg of F-BSLB4 and 500 µg of FITC-labeled Ulex europaeus agglutinin (F-Ulex; Vector Laboratories; n = 2) in 200 µl of 0.9% NaCl. Four mice were coperfused with F-BSLB4 and 3 x 105 of 4.2-µm and 2 x 105 of 6.0-µm polystyrene microspheres (Molecular Probes, Eugene, OR). Immediately before use, microspheres were vortex mixed, sonicated for 2 min, and then revortexed and diluted in the F-BSLB4/0.9% NaCl solution. Four to 7 min later, the hind limbs were perfused with 3–5 ml of 1% paraformaldehyde in PBS. The muscle and overlying skin from the ischemic limb, and contralateral limb muscle were harvested and postfixed 4–12 h in 2% paraformaldehyde.

Immunohistochemistry.
The identification and localization of cytokeratins 8, 18, and Notch 3 and Notch 4 were performed by using antibodies to each protein (clone CK5 for cytokeratin 18 from Sigma Chemical Co., St. Louis, MO; Notch-3 and -4 from Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and the Vectastain ABC and AEC kits (Vector Laboratories). The specificity of the Notch-3 and -4 antibodies was verified previously by Western analysis (16) . Cell cultures and tissue were fixed in 3.7% formaldehyde followed by a wash in 0.1% Triton X-100 in PBS for 5 min, and frozen unfixed tissues were used as well. The cultures were then incubated with either a primary antibody or a nonspecific IgG antibody for 2 h, followed by processing using the Vectastain ABC and AEC kits according to the manufacturer’s protocol. The identification of mouse endothelial cells in paraffin sections of EGFP-labeled tumor cells in reperfused tissues was performed using BSLB4 with Alexa 594 (red) dye (Molecular Probes). Images were obtained using a Zeiss Axioskop 2 microscope (Carl Zeiss, Inc., Thornwood, NY), a Spot 2 camera (Diagnostic Instruments, Inc., Sterling Heights, MI), and Zeiss Axiovision 2.0.5 software.

Confocal Microscopy.
Vibratome sections (200–250 µm thick) of mouse tissues were examined using a Zeiss LSM510 confocal microscope (Carl Zeiss, Inc.), using both the rhodamine and fluorescein filters for each image collected during the scanning process. The tomographic images were then converted into 32 projected images calculated from the original images throughout 53 degrees of rotation about the X-axis using the Zeiss LSM510-associated software. Individual projected images at each point of rotation were captured and an animated movie of the projected images revolving through a 53-degree arc was subsequently created.


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
A series of novel experiments were designed to test the putative biological significance of vasculogenic mimicry by aggressive human melanoma cells. In the present study, Ad-RFP (RFP-expressing Ad) or EGFP-labeled human cutaneous metastatic melanoma cells were injected i.m. into hind limbs of nude mice with surgically induced ischemia (resulting in blood flow <15% of normal). Five days postischemia, the presence of microspheres in limb vasculature (perfused via the aorta) demonstrated reperfusion of the limb as demonstrated by the presence of perfused beads within the vasculature (Fig. 1A)Citation . Mice were perfused via the aorta with F-BSLB4 and Ulex europaeus agglutinin (Fig. 1B)Citation to visualize the luminal side of the vascular wall, and confocal microscopy revealed Ad-RFP-labeled melanoma cells adjacent to the luminal label (Fig. 1, C and D)Citation . The three-dimensional reconstruction of confocal images into both vertical and horizontal planes delineates melanoma cells within vascular walls versus those external to the vasculature (Fig. 1D)Citation . To exclude the possibility that the Ad-vector targets murine vessels, similar experiments were performed using metastatic melanoma cells stably transfected with EGFP. Five days postischemia, histological cross-sections of muscular tissue, stained with mouse endothelial cell-specific BSLB4 (followed by streptavidin-conjugated Alexa dye 594), showed human melanoma cells adjacent to, and overlapping with, mouse endothelial cells in a linear arrangement (Fig. 1E)Citation . When poorly aggressive EGFP-labeled melanoma cells were introduced at the site of ischemia in separate experiments, they were not found 5 days postischemia (Fig. 1F)Citation .



View larger version (54K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Microscopic analyses of revascularization of nude mice ischemic hind limbs 5 days after surgical severing of femoral arterial branches followed by inoculation with 1 x 103 Ad-RFP- or EGFP-labeled human metastatic cutaneous melanoma cells (C8161) i.m. A, bright field microscopy of histological section shows perfusion of 10-mm beads (arrowheads) in neovasculature of ischemic muscle; B, confocal microscopy of mouse neovasculature perfused with F-BSLB4 and Ulex europaeus agglutinin delineating mouse vessels (green) and Ad-RFP-labeled tumor cells (red) with (C) branched neovasculature-containing tumor cells, confirmed in (D), with three-dimensional reconstruction showing melanoma cells in the lumenal side of the vascular wall (AVImovie@http://www.anatomy.uiowa.edu/pages/directory/faculty/images/vert_plane.avi). E, cross-section of EGFP-labeled metastatic melanoma cells colocalized with mouse endothelial cells labeled with BSLB4 and streptavidin Alexa dye 594 (red); F, poorly aggressive EGFP-labeled melanoma cells (C81–61) were not found with mouse endothelial cells (red). (A, x20; B–F, x40.)

 
The evidence shown here demonstrates the powerful influence of the microenvironment on the transendothelial differentiation of malignant melanoma cells needed for neovascularization and reperfusion of ischemic limbs. On the basis of the microarray analysis of the malignant cutaneous melanoma cells used in this study (13) , we suggested that the molecular signature of these tumor cells resembles that of a pluripotent, embryonic-like phenotype. An example of the plasticity of the aggressive melanoma phenotype has been demonstrated by the ability of these cells to engage in vasculogenic mimicry, the de novo formation of vasculogenic-like networks concomitant with the expression of vascular endothelial-cadherin (VE-cadherin) and other endothelial-associated genes (13 , 17 , 18) , and participation in neovascularization shown in the present study. It is evident from our investigation that the malignant, aggressive melanoma cells responded very differently to the ischemic environment than did the nonaggressive melanoma cells. Although a comparative study of the molecular profiles of these two phenotypes would have predicted a differential response, a functional assay was needed for proof of principle. Furthermore, recent studies have challenged previously held dogma regarding tissue-restricted differentiation of postnatal stem cells with convincing evidence that demonstrates pluripotency for mesenchymal, neural, and hematopoietic stem cells (for review, see Ref. 19 ). In addition, there are now documented examples of environmentally induced changes in differentiated cells, called transdifferentiation, which may help to elucidate the plasticity of cellular phenotypes (for review, see Ref. 20 ). Indeed, our results coincide with the recent observation that cardiomyocytes induced endothelial cells to transdifferentiate into cardiac muscle in ischemic hearts (20) . This study may provide clues as to the potential inductive nature of the ischemic skeletal muscle in our experiments. Other studies supporting our unique observations have shown that fibrocytes can induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo (21) ; and transformation of fibroblasts into endothelial cells during angiogenesis has also been shown (22) . Most intriguing is the potential significance of the expression of CD34, a progenitor cell antigen, normally found in endothelial cells and now reported in invasive malignant melanoma (23) .

During embryogenesis, the formation of primary vascular networks occurs via vasculogenesis, the in situ differentiation of mesodermal progenitor cells (angioblasts or hemangioblasts) to endothelial cells that form a primitive network (for review, see Refs. 1 , 3 ). Subsequent growth and remodeling of the vasculogenic network into a refined and efficient vasculature occurs via angiogenesis, the sprouting of new vessels from a preexisting network. Our present concept is that all blood vessels are derived from the same precursor cells in the embryo. However, how the ultimate vascular fate of these precursors is determined has remained somewhat elusive. In our investigation of ischemic limb reperfusion, we chose to examine selected Notch proteins known to promote the differentiation of endothelial cells into vascular networks (24 , 25) . As shown in Fig. 2Citation by immunohistochemistry, Notch 3 (Fig. 2A)Citation and Notch 4 (Fig. 2B)Citation were strongly expressed in the malignant melanoma cells but not in the nonspecific antibody control (Fig. 2C)Citation nor in the nonaggressive melanoma cells (Fig. 2D)Citation . Notch signaling molecules are integrally involved in cell-fate determination of stem cells and nonterminally differentiated cell types (24 , 25) . Alterations in Notch expression and signaling have also been implicated in human T-cell leukemia (26) , cervical carcinoma (27) , murine mammary carcinomas (28) , and prostatic tumor progression (29) . A recent report has provided new information regarding the signaling pathways involved in arterial-venous decisions by angioblast precursor cells, including Notch-Gridlock pathways and EphB2 and EphB4 expression (30) . Previous observations from our laboratory have shown the necessity for EphA2 in melanoma vasculogenic mimicry (18) , which may coincide with some of the findings in the angioblast cell-fate determination study.



View larger version (115K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Immunohistochemical localization of Notch proteins in 5-day reperfused mouse ischemic hind limbs and in cell culture. Notch 3 (A) and Notch 4 (B) expression (red) is intense in tissue sections containing metastatic melanoma cells (C8161) in reperfused ischemic muscle; C, control for Notch staining of a serial section treated with a nonspecific antibody; D, nonaggressive melanoma cells (C81–61) were essentially negative for Notch 3 (data not shown) and Notch 4 staining in tissue culture. A, B, and C, x40; D, x63.

 
Evaluation of the mouse reperfused limbs 20 days postischemia (Fig. 3)Citation showed well-formed vasculature with no detectable colocalized metastatic melanoma cells (Fig. 3A)Citation . Rarely, a melanoma cell was found external to the hind limb vasculature (Fig. 3, B and C)Citation , which had been completely reperfused, as shown by the perfusion of beads within the vasculature (Fig. 3D)Citation . By this time period, melanoma tumors had developed in other areas of the musculature (Fig. 3E)Citation , which suggested that the influence of the microenvironmental cues under ischemic conditions ceased to control the transendothelial phenotype function of the aggressive, malignant melanoma cells. Collectively, these observations advance our understanding of the remarkable inductive nature of the microenvironment on aggressive tumor cells that express vasculogenic/angiogenic molecules, together with cell-fate-determination signaling proteins, associated with a transendothelial function. These findings present new possibilities for therapeutic strategies and novel perspectives on tumor-cell plasticity.



View larger version (70K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Microscopic analyses of reperfused nude mice ischemic hind limbs at 20 days postischemia. A, confocal microscope-projected image of mouse vasculature (green) showing the relative absence of metastatic melanoma cells (C8161) with (B) demonstrating one Ad-RFP-labeled tumor cell extravascularly (red, arrowhead); C, cross-section of similar area showing one melanoma cell extravascularly (brown immunostaining for cytokeratins 8, 18), and (D) bright-field view showing perfused vasculature containing beads. E, microscopic view of H&E-stained tumor formed i.m. by C8161 metastatic melanoma cells. A, B, and D, x20; C, x63; E, x40.

 


   ACKNOWLEDGMENTS
 
We gratefully acknowledge the gift of cutaneous melanoma cell lines from Julie Buckmeyer and Dr. Frank Meyskens, Jr. (Chao Family Comprehensive Cancer Center, University of California-Irvine, Orange, CA).


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by NIH/National Cancer Institute Grants CA80318, CA59702 (to M. J. C. H.), CA83137 (to R. E. B. S.), DK55965 and DK59223 (to G. C. S.), HL46314 (to D. D. S.), and CA84065 (to L. M.). Back

2 To whom requests for reprints should be addressed, at Department of Anatomy and Cell Biology, The University of Iowa, 51 Newton Road, 1-100 BSB, Iowa City, IA 52242-1109. Phone: (319) 335-7755; Fax: (319) 335-7770; Back

3 The abbreviations used are: EGFP, enhanced green fluorescent protein; Ad, adenovirus; RFP, red fluorescent protein; Eph, Eph receptor tyrosine kinase; BSLB4, Bandeira simplicifolia lectin B4; F-BSLB4, FITC-labeled BSLB4. Back

Received 11/21/01. Accepted 12/11/01.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med., 6: 389-395, 2000.[Medline]
  2. Bissell M. J., Radisky D. Putting tumours in context. Nature Reviews Cancer, 1: 46-54, 2001.[Medline]
  3. Risau W. Mechanisms of angiogenesis. Nature (Lond.), 386: 671-674, 1997.[Medline]
  4. Liotta L. A., Kohn E. C. The microenvironment of the tumour-host interface. Nature (Lond.), 411: 375-379, 2001.[Medline]
  5. Folkman J. Clinical applications of research on angiogenesis. Seminars in Medicine of the Beth Israel Hospital, Boston. N. Engl. J. Med., 333: 1757-1763, 1995.[Free Full Text]
  6. Rak J., Kerbel R. S. Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Cancer Metastasis Rev., 15: 231-236, 1996.[Medline]
  7. Kumar R., Fidler I. J. Angiogenic molecules and cancer metastasis. In Vivo, 12: 27-34, 1998.[Medline]
  8. Chang Y. D., di Tomaso E., McDonald D. M., Jones R., Jain R. K., Munn L. L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. USA, 97: 14608-14613, 2000.[Abstract/Free Full Text]
  9. Warren B. A., Shubik P. The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab. Investig., 15: 464-478, 1966.[Medline]
  10. Timár J., Tóth J. Tumor sinuses: vascular channels. Pathol. Oncol. Res., 6: 83-86, 2000.[Medline]
  11. Pezzella F., Manzotti M., Di Bacco A., Viale G., Nicholson A. G., Price R., Ratclliffe C., Pastorino U., Gatter K. C., Altman D. G., Harris A. L., Pilotti S., Veronesi U. Evidence for a novel non-angiogenic pathway in breast cancer metastasis. Lancet, 355: 1787-1788, 2000.[Medline]
  12. Maniotis A. J., Folberg R., Hess A., Seftor E. A., Gardner L. M., Pe’er J., Trent J. M., Meltzer P. S., Hendrix M. J. C. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol., 155: 739-752, 1999.[Abstract/Free Full Text]
  13. Bittner M., Meltzer P., Chen Y., Jiang Y., Seftor E., Hendrix M., Radmacher M., Simon R., Yakhini Z., Ben-Dor A., Sampas N., Dougherty E., Wang E., Marincola F., Gooden C., Lueders J., Glatfelter A., Pollock P., Carpten J., Gillanders E., Leja D., Dietrich K., Beaudry C., Berens M., Alberts D., Sondak V., Hayward N., Trent J. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (Lond.), 406: 536-540, 2000.[Medline]
  14. Hendrix M. J. C., Seftor E. A., Chu Y-W., Seftor R. E. B., Nagle R. B., McDaniel K. M., Leong S. P. L., Yohem K. H., Leibovitz A. M., Meyskens F. L., Jr., Conaway D. H., Welch D. R., Liotta L. A., Stetler-Stevenson W. G. Coexpression of vimentin and keratins by human melanoma tumors cells: correlation with invasive and metastatic potential. J. Natl. Cancer Inst. (Bethesda), 84: 165-174, 1992.[Abstract/Free Full Text]
  15. Schatteman G. C., Hanlon H. D., Jiao C., Dodds S. G., Christy B. A. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J. Clin. Investig., 106: 571-578, 2000.[Medline]
  16. Cheng P., Zlobin A., Volgina V., Gottipati S., Osborne B. A., Simel E. J., Miele L., Gabrilovich D. Notch-1 regulates NF-{kappa}B activity in hemopoietic progenitor cells. J. Immunol., 167: 4458-4467, 2001.[Abstract/Free Full Text]
  17. Hendrix M. J. C., Seftor E. A., Meltzer P. S., Gardner L. M. G., Hess A. R., Kirschmann D. A., Schatteman G. C., Seftor R. E. B. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl. Acad. Sci. USA, 98: 8018-8023, 2001.[Abstract/Free Full Text]
  18. Hess A. R., Seftor E. A., Gardner L. M. G., Carles-Kinch K., Schneider G. B., Seftor R. E. B., Kinch M. S., Hendrix M. J. C. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res., 61: 3250-3255, 2001.[Abstract/Free Full Text]
  19. Anderson D. J., Gage F. H., Weissman L. Can stem cells cross lineage boundaries?. Nat. Med., 7: 393-395, 2001.[Medline]
  20. Condorelli G., Borello U., De Angelis L., Latronico M., Sirabella D., Coletta M., Galli R., Balconi G., Follenzi A., Frati G., Cusella De Angelis M. G., Gioglio L., Amuchastegui S., Adorini L., Naldini L., Vescovi A., Dejana E., Cossu G. Cardiomyocytes induce endothelial cells to transdifferentiate into cardiac muscle: implications for myocardium regeneration. Proc. Natl. Acad. Sci. USA, 98: 10733-10738, 2001.[Abstract/Free Full Text]
  21. Hartlapp I., Abe R., Saeed R. W., Peng T., Voelter W., Bucala R., Metz C. N. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J., 15: 2215-2224, 2001.[Abstract/Free Full Text]
  22. Kazunori K., Fujiwara T. Transformation of fibroblasts into endothelial cells during angiogenesis. Cell Tissue Res., 278: 625-628, 1994.[Medline]
  23. Hoang M. P., Selim M. A., Bentley R. C., Burchette J. L., Shea C. R. CD34 expression in desmoplastic melanoma. J. Cutan. Pathol., 28: 508-512, 2001.[Medline]
  24. Uyttendaele H., Ho J., Rossant J., Kitajewski J. Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc. Natl. Acad. Sci. USA, 98: 5643-5648, 2001.[Abstract/Free Full Text]
  25. Gridley T. Notch signaling during vascular development. Proc. Natl. Acad. Sci. USA, 98: 5377-5378, 2001.[Free Full Text]
  26. Ellisen L. W., Bird J., West D. C., Soreng A. L., Reynolds T. C., Smith S. D., Sklar J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell, 66: 649-661, 1991.[Medline]
  27. Robbins J., Blonel B. J., Gallahan D., Callahan R. Mouse mammary tumor gene Int-3: a member of the Notch gene family transforms mammary epithelial cells. J. Virol., 66: 2594-2599, 1992.[Abstract/Free Full Text]
  28. Zagouras P., Stifani S., Blaumueller C. M., Carcangiu M. L., Artavanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc. Natl. Acad. Sci. USA, 92: 6414-6418, 1995.[Abstract/Free Full Text]
  29. Shou J., Ross S., Koeppen H., de Sauvage F. J., Gao W-Q. Dynamics of Notch expression during murine prostate development and tumorigenesis. Cancer Res., 61: 7291-7297, 2001.[Abstract/Free Full Text]
  30. Zhong T. P., Childs S., Leu J. P., Fishman M. C. Gridlock signaling pathway fashions the first embryonic artery. Nature (Lond.), 414: 216-220, 2001.[Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
J. Cedervall, S. Jamil, L. Prasmickaite, Y. Cheng, M. Eskandarpour, J. Hansson, G. M. Maelandsmo, U. Ringborg, M. Gulyas, H. S. Zhen, et al.
Species-Specific In vivo Engraftment of the Human BL Melanoma Cell Line Results in an Invasive Dedifferentiated Phenotype Not Present in Xenografts
Cancer Res., May 1, 2009; 69(9): 3746 - 3754.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
K. M. R. Bhat, N. Maddodi, C. Shashikant, and V. Setaluri
Transcriptional regulation of human MAP2 gene in melanoma: role of neuronal bHLH factors and Notch1 signaling
Nucleic Acids Res., August 11, 2006; 34(13): 3819 - 3832.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. M. Kulesa, J. C. Kasemeier-Kulesa, J. M. Teddy, N. V. Margaryan, E. A. Seftor, R. E. B. Seftor, and M. J. C. Hendrix
Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment
PNAS, March 7, 2006; 103(10): 3752 - 3757.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Miele
Notch Signaling
Clin. Cancer Res., February 15, 2006; 12(4): 1074 - 1079.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Anghelina, P. Krishnan, L. Moldovan, and N. I. Moldovan
Monocytes/Macrophages Cooperate with Progenitor Cells during Neovascularization and Tissue Repair: Conversion of Cell Columns into Fibrovascular Bundles
Am. J. Pathol., February 1, 2006; 168(2): 529 - 541.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J.-Z. Qin, L. Stennett, P. Bacon, B. Bodner, M. J.C. Hendrix, R. E.B. Seftor, E. A. Seftor, N. V. Margaryan, P. M. Pollock, A. Curtis, et al.
p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas
Mol. Cancer Ther., August 1, 2004; 3(8): 895 - 902.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Walker-Daniels, A. R. Hess, M. J.C. Hendrix, and M. S. Kinch
Differential Regulation of EphA2 in Normal and Malignant Cells
Am. J. Pathol., April 1, 2003; 162(4): 1037 - 1042.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Herlyn, M. Padarathsingh, L. Chin, M. Hendrix, D. Becker, M. Nelson, Y. DeClerck, J. McCarthy, and S. Mohla
New Approaches to the Biology of Melanoma: A Workshop of the National Institutes of Health Pathology B Study Section
Am. J. Pathol., November 1, 2002; 161(5): 1949 - 1957.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. E. B. Seftor, E. A. Seftor, D. A. Kirschmann, and M. J. C. Hendrix
Targeting the Tumor Microenvironment with Chemically Modified Tetracyclines: Inhibition of Laminin 5 {gamma}2 Chain Promigratory Fragments and Vasculogenic Mimicry
Mol. Cancer Ther., November 1, 2002; 1(13): 1173 - 1179.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. P. Young, A. A. Hofling, and M. S. Sands
VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients
PNAS, September 3, 2002; 99(18): 11951 - 11956.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hendrix, M. J. C.
Right arrow Articles by Schatteman, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hendrix, M. J. C.
Right arrow Articles by Schatteman, G. C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online